Figure 3 | Scientific Reports

Figure 3

From: Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers

Figure 3

In vitro analysis of bortezomib-induced cell cycle arrest and apoptosis in A-375 melanoma cells. (a,b) Cell cycle distribution analysis showing G2/M cell cycle arrest in A-375 cells following 24h treatment with 50 nM bortezomib. The one-way ANOVA test was used to calculate statistically significant differences between the proportion of cells present in different cell cycle phases (G1, S, and G2/M phases). Not significant (P > 0.05); *P < 0.05; **P ≤ 0.01; ***P ≤ 0.001. Only statistically significant differences are shown in the figure. (c,d) Annexin V analysis showing a high proportion of early apoptotic A-375 melanoma cells after 24h bortezomib treatment, and necrotic – late apoptotic cells after 72h treatment with 50 nM bortezomib. The one-way ANOVA test was used to determine statistically significant differences between the proportion of necrotic-late apoptotic or early apoptotic cells at different bortezomib concentrations. Not significant (P > 0.05); *P < 0.05; **P ≤ 0.01; ***P ≤ 0.001. Only bars with significant differences between the same state and at different bortezomib concentrations were shown in the figure.

Back to article page